Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rare gynecologic malignancies.

J C Schink1, J R Lurain

  • 1Northwestern University Medical School, Prentice Women's Hospital, Chicago, IL 60611.

Current Opinion in Obstetrics & Gynecology
|February 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A papanicolaou smear with psammona bodies.

Journal of lower genital tract disease·2015
Same author

The association between allogeneic perioperative blood transfusion on tumour recurrence and survival in patients with advanced ovarian cancer.

Transfusion medicine (Oxford, England)·2011
Same author

Malignant melanoma of the vulva: an extension of cutaneous melanoma?

Gynecologic oncology·2011
Same author

Participation of the general gynecologist in surgical staging of endometrial cancer: analysis of cost and perioperative outcomes.

Gynecologic oncology·2006
Same author

Saline contrast sonohysterography and directed extraction, resection and biopsy of intrauterine pathology using a Uterine Explora Curette.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2005
Same author

Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2003

Rare gynecologic tumors like fallopian tube and peritoneal carcinomas mimic ovarian cancer, showing poor survival. Uterine sarcomas are highly lethal, while gestational trophoblastic tumors are typically curable, even with metastasis.

Area of Science:

  • Gynecologic Oncology
  • Rare Tumor Biology
  • Cancer Treatment and Outcomes

Background:

  • Fallopian tube and peritoneal papillary serous carcinomas present similarly to advanced ovarian cancer.
  • Uterine sarcomas represent a highly lethal group of gynecologic malignancies with poor prognoses.
  • Gestational trophoblastic tumors exhibit a high curability rate, even in metastatic stages.

Purpose of the Study:

  • To review the clinical features, staging, and current treatment strategies for rare gynecologic tumors.
  • To compare the therapeutic responses and survival rates of distinct rare gynecologic malignancies.
  • To highlight the differential outcomes and management approaches for fallopian tube carcinoma, peritoneal carcinoma, uterine sarcoma, and gestational trophoblastic tumors.

Main Methods:

Related Experiment Videos

  • Literature review of clinical features.
  • Analysis of staging systems for gynecologic malignancies.
  • Summary of current treatment protocols and their efficacy.
  • Comparative analysis of survival data for different tumor types.

Main Results:

  • Fallopian tube and peritoneal carcinomas share treatment similarities with ovarian cancer, achieving an 80% response rate but only a 20% 5-year survival.
  • Uterine sarcomas demonstrate frequent recurrence and mortality despite early diagnosis and aggressive treatment.
  • Gestational trophoblastic tumors are generally curable, irrespective of metastatic spread.

Conclusions:

  • Rare gynecologic tumors necessitate tailored diagnostic and therapeutic strategies.
  • Significant disparities exist in the prognosis and curability among different rare gynecologic malignancies.
  • Further research into novel therapeutic approaches is warranted for tumors with poor survival outcomes, such as uterine sarcomas and advanced ovarian cancer mimics.